Anxioselective anxiolytics.
D000241:Adenosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000818:Animals; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy*; D053961:Azabicyclo Compounds; D001569:Benzodiazepines; D001923:Brain Chemistry; D004347:Drug Interactions; D004974:Etazolate / Q000627:therapeutic use; D006801:Humans; D008970:Molecular Weight; D010879:Piperazines / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D011724:Pyridazines / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D011956:Receptors, Cell Surface / Q000378:metabolism; D011963:Receptors, GABA-A; D013329:Structure-Activity Relationship; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D014151:Anti-Anxiety Agents; D053961:Azabicyclo Compounds; D010879:Piperazines; D011720:Pyrazoles; D011724:Pyridazines; D011804:Quinolines; D011956:Receptors, Cell Surface; D011963:Receptors, GABA-A; C515050:zopiclone; D001569:Benzodiazepines; D005680:gamma-Aminobutyric Acid; C021604:CL 218872; C025960:N(6)-(2-(4-chlorophenyl)bicyclo(2.2.2.)-octyl)(3)-adenosine; C034704:2-(4-chlorophenyl)-2,5-dihydropyrazolo(4,3-c)quinoline-3(3H)-one; C033830:2-phenylpyrazolo(4,3-c)quinolin-3(5H)-one; C006315:cartazolate; D004974:Etazolate; C030078:pipequaline; D000241:Adenosine